Old Mission Capital’s Sage Therapeutics SAGE Stock Holding History

Old Mission Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-9,063	Closed	-$554K	–	651
2020 Q3	$554K	Buy	+9,063	New	+$459K	0.04%	282

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Old Mission Capital's SAGE Position: Q4 2020 in Review

Old Mission Capital sold out of Sage Therapeutics (SAGE) in Q4 2020, closing a stake of 9,063 shares — an estimated $554K sold.

Old Mission Capital first reported a position in SAGE in Q3 2020 and held it in 1 quarter. The position peaked at $554K in Q3 2020. 248 funds tracked by Wall St. Rank hold SAGE as of Q4 2020.

Old Mission Capital reported no remaining Sage Therapeutics position as of Q4 2020 after selling out during the quarter.
Old Mission Capital sold 9,063 Sage Therapeutics shares in Q4 2020, an estimated $554K.
Old Mission Capital first reported a position in Sage Therapeutics in Q3 2020 and held it in 1 quarter.
Old Mission Capital's Sage Therapeutics position peaked at $554K in Q3 2020.
248 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2020.

Based on Old Mission Capital's 13F filing for Q4 2020, filed 17 Feb 2021.